A Champion of Research: Gaylia Meitzen
Gaylia Meitzen lived her life with joy and courage. Though she was diagnosed with type 1 diabetes at age 16, she enthusiastically took up fishing, boating, golfing and traveling, and she even climbed Mount Rainier. She loved talking with young people with type 1 diabetes to encourage and mentor them.
And when she learned about BRI’s mission to fight autoimmune diseases including type 1 diabetes, it became her passion to support the Institute and research. She joined the BRI Board of Directors in 2007, served as chair of the BRI Development Committee and spoke at numerous events about living with type 1 diabetes and the research at BRI. She also provided generous and inspiring philanthropic support. On March 23, 2013, Gaylia passed away. In her honor, the BRI auditorium has been named The Gaylia R. Meitzen Auditorium, acknowledging her extraordinary commitment to nurture and foster BRI’s mission.
“Gaylia Meitzen was a tremendous advocate for BRI and for our diabetes research efforts, serving on our Board of Directors for many years,” says BRI Director Gerald Nepom, MD, PhD. “Her advice, energy and commitment to our mission will be sorely missed. We are honored to dedicate The Gaylia R. Meitzen Auditorium in her memory and to continue her legacy.”
“For Gaylia, it’s always been about the promise of research, as she’s demonstrated through her support for many years,” says her husband, Steve Quintrell. “She saw research as hope for the cure.”
You Might Also Like
Innovation Fund Spotlight: Pioneering a New Generation of Tetramers
In the late 1990s, Bill Kwok, PhD, pioneered MHC class II tetramers, a game-changing tool in immunology research. Tetramers have fueled countless research breakthroughs because they enable scientists to find extremely rare cells and extract them to study in precise detail.
New Technology Opens the Door to Understanding the Earliest Stages of T1D
Eddie James, PhD, earned a new grant to explore early cell changes that lead to T1D, using a new tool pioneered at BRI.
Game-Changing Treatment for T1D Enters Clinical Trials
A new T1D treatment, built on decades of research at BRI and other institutions, has entered human clinical trials.
Immuno-what? Hear the latest from BRI
Keep up to date on our latest research, new clinical trials and exciting publications.